Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 12/20 | 0.74 |
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.58 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.58 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6236811 | 0.90 | MAPKAPK2 (0.64) | MAPKAPK2MAPKAPK5SIRT1MAPKAPK3MAPT | |
| SCHEMBL6360694 | 0.89 | MAPKAPK2 (0.62) | MAPKAPK2MAPKAPK5SIRT1MAPKAPK3MAPT | |
| SCHEMBL1658785 | 0.85 | MAPKAPK2 (1.00) | MAPKAPK2MAPKAPK5SIRT1MAPKAPK3MAPT | |
| SCHEMBL6241557 | 0.83 | MAPKAPK2 (1.00) | MAPKAPK2MAPKAPK5SIRT1MAPKAPK3MAPT | |
| SCHEMBL6239272 | 0.81 | MAPKAPK2 (0.80) | MAPKAPK2MAPKAPK5SIRT1MAPKAPK3MAPT | |
| SCHEMBL6239833 | 0.79 | MAPKAPK2 (0.78) | MAPKAPK2MAPKAPK5SIRT1MAPKAPK3MAPT | |
| SCHEMBL6241878 | 0.79 | MAPKAPK2 (0.78) | MAPKAPK2MAPKAPK5SIRT1MAPKAPK3MAPT | |
| Trifluoroacetic Acid SCHEMBL6358930 | 0.79 | MAPKAPK2 (0.86) | MAPKAPK2MAPKAPK5SIRT1MAPKAPK3MAPT | |
| SCHEMBL6236968 | 0.78 | MAPKAPK2 (0.81) | MAPKAPK2MAPKAPK5SIRT1MAPKAPK3MAPT | |
| SCHEMBL6235510 | 0.78 | MAPKAPK2 (0.81) | MAPKAPK2MAPKAPK5SIRT1MAPKAPK3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005009370-A2 | BETA-CARBOLINE COMPOUNDS AND ANALOGUES THEREOF AND THEIR USE AS MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | MAPKAPK2 1/4885MAPKAPK5 34/4885SIRT1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.